Grants Search Results

Medulloblastoma is the most common malignant brain tumor. There is an urgent need to develop novel therapies for children with medulloblastoma. Dr. Van Meir and his team are studying the importance of the loss of tumor suppressor BAI1 in medulloblastoma. Such new knowledge has the potential to reveal new ways to treat this disease.

Many currently used chemotherapeutic drugs have severe toxic side effects and a significant number of cancer patients do not respond well to chemotherapy. Thus, developing more effective and less harmful new anticancer drugs remains significant and challenging. Dr. Zhou's team has discovered several small molecule chemical compounds that are stronger to kill cancer cells, and less toxic to normal cells than currently used chemotherapeutic drugs. Dr. Zhou is studying the mechanism by which these compounds kill cancer but not normal human cells, and how to develop these compounds as effective and safe therapeutic drugs for treating refractory cancer patients.

Neuroblastoma is a common childhood cancer. Cancers happen because of mutations (mistakes) in the genetic code within them, and knowing which specific mutation happened in each particular cancer should help doctors improve their treatments. Dr. Hogarty's team discovered that some neuroblastomas have mutations in a specific gene, ARID1, and that these tumors are especially difficult to cure. Dr. Hogarty is studying this gene more since it determines how nerve cells behave, and neuroblastoma arises from mutated nerve cells. This may give us insight into new ways to treat neuroblastoma.

Despite the toxic effects of current treatment for children and young adults with AML, overall survival remains poor because of recurrent leukemia. If their AML does not respond to chemotherapy after relapse, chances for survival are low. This team has identified important changes in AML that can be exploited to develop more effective and less toxic treatments using new types of drugs. The consortium focuses on showing that these pathways are needed for leukemia survival, and developing pathway-directed clinical trials to improve outcomes for this group of patients with no other treatment options. Awarded to Phoenix Children's Hospital and transferred to Fred Hutchinson Cancer Research Center. Funds administered by Fred Hutchinson Cancer Research Center.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Pathway Directed Treatment for Refractory AML Consortium. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This team has identified a subset of childhood Acute Lymphoblastic Leukemia (ALL) with specific genetic abnormalities in the leukemia cells (Ph-like ALL) that has poor survival. Some Ph-like ALL patients have genetic abnormalities that make their leukemia cells sensitive to a targeted therapy (dasatinib), which has many fewer side effects than chemotherapy. This consortium is using a COG clinical trial to help identify which children should respond to dasatinib, and then will add this targeted therapy to their chemotherapy to try to improve survival. Awarded at the University of Colorado and transferred to the Children's Hospital of Philadelphia. Funds administered by the Children's Hospital of Philadelphia.

Neuroblastoma is one of the most common solid tumors of childhood, and patients have very low survival if it recurs after initial treatment. Natural killer (NK) cells are white blood cells that are part of your body's natural defense against cancer, and these cells are particularly good at killing neuroblastoma when they work together with immune stimulators and anti-cancer antibodies. This team has developed a new way to grow large numbers of very active NK cells. The project is testing whether NK cells in combination with the anti-neuroblastoma antibody, ch14.18, and the immune activator, lenalidomide, will improve survival for children with neuroblastoma. Awarded at University of Texas M.D. Anderson Cancer Center and transferred to The Research Institute at Nationwide Children's. Funds administered by The Research Institute at Nationwide Children's Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Multimodal immunotherapy for neuroblastoma Consortium. For a description of this project, see the consortium grant made to the lead institution: The Research Institute at Nationwide Children's Hospital, Columbus, OH.